An Overview of MASH: Advancements in Diagnosis, Treatment, and the Role of Real-World DataRead more →
Addressing the Burden of Hidradenitis Suppurativa: The Often-Hidden Impact on Quality of LifeRead more →
Patient-Centric Data Capture Fuels Growth of Target RWE Longitudinal, Real-World Dermatology StudiesRead more →
New Patient-Reported Outcome Insights from Target RWE: NASH-CHECK Reveals Stability Over Time and Worse Scores Among Those with Decompensated Cirrhosis of Patients with MASLDRead more →
Target RWE Highlights GLP-1 Receptor Agonists in Patients with Metabolic Dysfunction Associated Steatotic Liver Disease at The Liver Meeting 2024Read more →
ACG 2024: Target RWE Presents Key MASH and EGIDs Data from Leading Liver Disease & Gastroenterology Real-World RegistriesRead more →
Transforming Healthcare Through Data: Ewa J. Kleczyk on Precision Medicine, Diversity, and AI ChallengesRead more →
Real World TARGET-NASH Analysis Shows High Concordance Between New MASLD Definitions and Prior TARGET-NASH Pragmatic DefinitionsRead more →
GLP-1 Use and NASH-CHECK Patient-Reported Outcomes Studies from Target RWE Presented at EASL 2024Read more →
Real-World Evidence Leader in Inflammatory Bowel Disease, Target RWE, Announces Expanded Footprint with TARGET-GASTRO Registry of 30,000+ Patients At Digestive Disease WeekRead more →
Patient-Reported Outcomes Data from Longest Running Dermatology Study: TARGET-DERM AA Poster Presented at American Academy of Dermatology (AAD) 2024Read more →
Overcoming Scalability Challenges in Real-World Data Processing for Transformative Patient CareRead more →
TARGET-NASH Offers Unprecedented Glimpse into Growing Public Health Concerns with Few Treatment OptionsRead more →
Leveraging Real-World Evidence with Analytics: 3 Essential Components to Capture a 360-Degree View of Your Patient PopulationRead more →
Event Recap Blog: TARGET-NASH Analysis Presented at ISPOR 2023 and Target RWE Leaders Present at PMSA 2023Read more →
Real World Evidence Leader Target RWE Shares Expansion and Update on TARGET-GASTRO Longitudinal Study During Digestive Disease Week 2023Read more →
Validation of a Pragmatic Clinical Risk-Based Classification of NASH - New Supporting Real World Evidence from TARGET-NASHRead more →
Longest Running Real World Dermatology Registry, TARGET-DERM, Offers Deep Insight into Complex DiseasesRead more →
New Approaches for Developing Real-World Evidence Presented by Target RWE at the 2022 International Conference on Pharmacoepidemiology (ICPE)Read more →
Target RWE New Brand, Research, and Advanced Real World Evidence Analytics Showcased at International Conference on Pharmacoepidemiology (ICPE) 2022Read more →
Real-World Data Finds High Prevalence of Pruritus (Itching) and Fatigue, Low Levels of Treatment in Primary Biliary Cholangitis PopulationRead more →
Nonalcoholic Fatty Liver Disease (NAFLD) Research from Target RWE's Real-World Study Presented at International Liver Congress 2022Read more →
New Data Presented at DDW 2022 Shows Nearly Two-Fold Risk of Loss of Remission in Ulcerative Colitis Patients Who Had Histologic Inflammation on Baseline BiopsyRead more →
Large Real-World Study Uncovers Higher Prevalence of Non-Alcoholic Fatty Liver Disease Markers, Liver Biopsy, and Cirrhosis in ChildrenRead more →
TARGET-IBD Study Reveals Nearly a Third of Patients with Inflammatory Bowel Disease Did Not Undergo Objective Assessment Prior to Biologic Dose Change, DiscontinuationRead more →
Peer-Reviewed Target RWE Study Finds Wide Variance in Nonalcoholic Steatohepatitis (NASH) Pathology ReportingRead more →
Update from Paris NASH 2021: New Target RWE Nonalcoholic Steatohepatitis (NASH) Data Presented at This Year's MeetingRead more →
Target RWE HBV Research on Antiviral Treatments, Characteristics, and Clinical Outcomes Published in Digestive Diseases and SciencesRead more →
Target RWE Study Shows Significant Differences in Medication Use Among Older Patients with IBD Compared to Younger PatientsRead more →
TARGET-NASH Study Finds Statins Underutilized in Patients with NAFLD and At-Risk of Heart DiseaseRead more →
Target RWE COVID-19 Data: Real-World Evidence Analysis Shows 3.6% of COVID-19 Hospitalized Patients Discharged Alive Required ReadmissionRead more →
Target RWE Research Presented at DDW 2021 Shows High Rates of Biologic Combination Therapy and Previous Biologic Exposure in IBD PopulationRead more →
TARGET-NASH Real-World Study Reveals Two Thirds Of Patients With NAFLD Had No Record Of Liver BiopsyRead more →
Target RWE Acquires NoviSci Inc., Adding Significant Analytical Capabilities to Leading Real-World Evidence PlatformRead more →
Target RWE Data Presented at AASLD Virtual Meeting Provides Important Updates for NASH and PBC CommunitiesRead more →
TARGET-NASH Data Publication Finds Nearly One In Five Patients With NAFLD Have Prior Prescription Opioid UseRead more →
Asian Lean Patients With NAFLD Are 53% Less Likely To Have Cirrhosis, Cardiovascular, And Metabolic Diseases - Latest Data Findings Released From TARGET-NASH StudyRead more →
Target RWE Builds Growing COVID-19 Data Set of 70,000+ Patients, Announces Published Data FindingsRead more →
TARGET-IBD Research Receives Presidential Poster Award And Outstanding Presenter Award At 2019 American College Of Gastroenterology Annual Scientific MeetingRead more →
Intercept Announces OCALIVA (OBETICHOLIC ACID) Data in PBC to be Presented at the 2016 AASLD Annual MeetingRead more →
